---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-26-000112"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2026-08-06T11:33:24+00:00"
generated_at: "2026-08-06T11:35:09.277017+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexicon Q2 net loss $31.8M; SONATA-HCM enrollment complete; ZYNQUISTA NDA resubmission Q4 2026

## Summary
- Net loss $31.8M ($0.07/share) vs net income $3.3M ($0.01/share) in Q2 2025; total revenue $0.7M (all INPEFA) vs $28.9M (incl $27.6M licensing) YoY.
- Cash and investments $190.6M at June 30, 2026, up from $125.2M at Dec 31, 2025; $100M Hercules loan facility entered, $55M drawn.
- SONATA-HCM Phase 3 enrollment completed (exceeded 500 patients); top-line data expected Q1 2027.
- ZYNQUISTA NDA resubmission for T1D expected Q4 2026, pending STENO1 safety data.
- LX9851 Phase 1 by Novo Nordisk ongoing; Lexicon eligible for up to $1B milestones plus royalties.

## SEC filing metadata
- accession: 0001062822-26-000112
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2026-08-06T11:33:24+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000112/0001062822-26-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282226000112/lxrx-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-26-000112
- JSON: https://secwatch.observer/filing/0001062822-26-000112.json
- Plain text: https://secwatch.observer/filing/0001062822-26-000112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.